Acta Med. 2017, 60: 167-170

https://doi.org/10.14712/18059694.2018.15

SGLT-2 Inhibitors: Are They a Promising Treatment Option in T2DM Patients with NAFLD?

Dimitrios Patoulias

Department of Internal Medicine, General Hospital of Veria, Veria, Greece

Received September 8, 2017
Accepted February 6, 2018

References

1. Hazlehurst JM, Woods C, Marjot T, Cobbold JF, Tomlinson JW. Non-alcoholic fatty liver disease and diabetes. Metabolism 2016, 65(8): 1096–1108. <https://doi.org/10.1016/j.metabol.2016.01.001> <PubMed>
2. Taylor S, Blau J, Rother, K. SGLT2 Inhibitors May Predispose to Ketoacidosis. J. Clin. Endocrinol Metab 2015; 100(8): 2849–2852. <https://doi.org/10.1210/jc.2015-1884> <PubMed>
3. Daniele G, Xiong J, Solis-Herrera C, et al. Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes. Diabetes Care 2016; 39(11): 2036–2041. <https://doi.org/10.2337/dc15-2688> <PubMed>
4. Ferrannini E, Baldi S, Frascerra S, et al. Shift to fatty substrate utilization in response to sodium–glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes 2016; 65: 1190–1195. <https://doi.org/10.2337/db15-1356>
5. Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium- glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014; 124(2): 499–508. <https://doi.org/10.1172/JCI72227> <PubMed>
6. Kamei S, Iwamoto M, Kameyama M, et al. Effect of Tofogliflozin on Body Composition and Glycemic Control in Japanese Subjects with Type 2 Diabetes Mellitus. Journal of Diabetes Research 2018, Article ID 6470137, 6 pages.
7. Honda Y, Imajo K, Kato T, Kessoku T, Ogawa Y, Tomeno W, et al. The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice. PLoS ONE 2016; 11(1): e0146337. <https://doi.org/10.1371/journal.pone.0146337> <PubMed>
8. Komiya C, Tsuchiya K, Shiba K, Miyachi Y, Furuke S, Shimazu N, et al. Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction. PLoS ONE 2016; 11(3): e0151511. <https://doi.org/10.1371/journal.pone.0151511> <PubMed>
9. Nakano S, Katsuno K, Isaji M, et al. Remogliflozin Etabonate Improves Fatty Liver Disease in Diet-Induced Obese Male Mice. J Clin Exp Hepatol 2015; 5(3): 190–198. <https://doi.org/10.1016/j.jceh.2015.02.005> <PubMed>
10. Tahara A, Kurosaki E, Yokono M, et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol 2013; 715(1–3): 246–255. <https://doi.org/10.1016/j.ejphar.2013.05.014>
11. Hayashizaki-Someya Y, Kurosaki E, Takasu T, et al. Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats. Eur J Pharmacol 2015; 754: 19–24. <https://doi.org/10.1016/j.ejphar.2015.02.009>
12. Qiang S, Nakatsu Y, Seno Y, et al. Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus. Diabetol Metab Syndr 2015; 7: 104. <https://doi.org/10.1186/s13098-015-0102-8> <PubMed>
13. Ji W, Zhao M, Wang M, Yan W, Liu Y, Ren S, et al. Effects of canagliflozin on weight loss in high-fat diet-induced obese mice. PLoS ONE 2017; 12(6): e0179960. <https://doi.org/10.1371/journal.pone.0179960> <PubMed>
14. Jojima T, Tomotsune T, Iijima T, Akimoto K, Suzuki K, Aso Y. Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes. Diabetol Metab Syndr 2016; 8: 45. <https://doi.org/10.1186/s13098-016-0169-x> <PubMed>
15. Obara K, Shirakami Y, Maruta A, et al. Preventive effects of the sodium glucose cotransporter 2 inhibitor tofogliflozin on diethylnitrosamine- induced liver tumorigenesis in obese and diabetic mice. Oncotarget 2017; 8(35): 58353–58363. <https://doi.org/10.18632/oncotarget.16874> <PubMed>
16. Tobita H, Sato S, Miyake T, Ishihara S, Kinoshita Y. Effects of dapagliflozin on body composition and liver tests in patients with non-alcoholic steatohepatitis associated with type 2 diabetes mellitus: A prospective, open-label, uncontrolled study. Curr Ther Res Clin Exp 2017; 87: 13–19. <https://doi.org/10.1016/j.curtheres.2017.07.002> <PubMed>
17. Ito D, Shimizu S, Inoue K, et al. Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial. Diabetes Care 2017; 40(10): 1364–1372. <https://doi.org/10.2337/dc17-0518>
18. Leiter LA, Forst T, Polidori D, Balis DA, Xie J, Sha S. Effect of canagliflozin on liver function tests in patients with type 2 diabetes. Diabetes Metab 2016; 42(1): 25–32. <https://doi.org/10.1016/j.diabet.2015.10.003>
19. Okhi T, Isogawa A, Toda N, Tagawa K. Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors. Clin Drug Investig 2016; 36(4): 313–319.
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal

Archive